Posted by kinasepro on September 9, 2008
Roche Palo Alto just published 3E7O: JNK2 (7x mutant) bound to an indazole:
Which brings up that nearly two years ago I suggested CC-401 may be from an ’06 Celgene application. Right flavor wrong compound, the drawn compound is CG-930 (IND filed Dec 18, 2007 – claimed in Ph1 for fibrotic diseases). As NCI suggests CC-401 is an SP-600125 analog which incidentally is no longer on the CG pipeline.
That’s life on the edge for yah.